NHS Approves New Ovarian Cancer Treatment, Benefiting Hundreds of Women
Hundreds of women to benefit from breakthrough ovarian cancer treatment in UK
The Independent
Image: The Independent
The NHS has approved mirvetuximab soravtansine, a new treatment for women with platinum-resistant ovarian cancer, marking the first such approval in 20 years. This targeted therapy offers hope to around 400 patients annually, significantly improving their quality of life and survival rates.
- 01Mirvetuximab soravtansine, also known as Elahere, is now approved for NHS use for specific ovarian, fallopian tube, or peritoneal cancers.
- 02This treatment represents the first new ovarian cancer therapy approved by NHS in two decades.
- 03Clinical trials indicate that the drug can extend survival by approximately four months compared to chemotherapy alone.
- 04Around 400 women in England are expected to benefit from this treatment each year.
- 05Patient testimonials highlight improved quality of life and reduced side effects compared to traditional chemotherapy.
Advertisement
In-Article Ad
The National Institute for Health and Care Excellence (NICE) has approved mirvetuximab soravtansine, a groundbreaking treatment for women with hard-to-treat ovarian cancer, specifically those with platinum-resistant forms of the disease. This approval is a significant milestone as it is the first new treatment for ovarian cancer in the NHS in 20 years. The targeted therapy, developed by AbbVie, works by attaching to cancer cells and destroying them, and is administered via a drip every three weeks. Clinical trials have shown that it can improve patient survival by about four months compared to traditional chemotherapy. NICE estimates that approximately 400 women in England will benefit from this treatment annually. Experts and patient advocates have expressed optimism, noting that this new option offers hope and improved quality of life for women who previously faced limited choices after chemotherapy failure. Personal accounts from patients, such as Patricia Hill, emphasize the treatment's positive impact on daily life and well-being.
Advertisement
In-Article Ad
The approval of mirvetuximab soravtansine provides a new treatment option for women with limited choices after chemotherapy, potentially enhancing their quality of life and survival rates.
Advertisement
In-Article Ad
Reader Poll
How do you feel about the new ovarian cancer treatment approved by the NHS?
Connecting to poll...
More about National Institute for Health and Care Excellence
Read the original article
Visit the source for the complete story.